OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.17 +0.00 (+0.96%) As of 11/11/2026 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NWBO alerts:Sign Up Key Stats Today's Range$0.16▼$0.1750-Day Range$0.15▼$0.1852-Week Range$0.14▼$0.34Volume1.47 million shsAverage Volume4.68 million shsMarket Capitalization$307.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Northwest Biotherapeutics is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer. The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors. These candidates are not established treatments, and their development is subject to clinical and regulatory review. Northwest Biotherapeutics is headquartered in the United States and has manufacturing operations in the United Kingdom. Its work has included clinical research in multiple countries.AI Generated. May Contain Errors. Read More Northwest Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreNWBO MarketRank™: 0.1220152191 of 5 starsNorthwest Biotherapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Northwest Biotherapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.91% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 7.78.Change versus previous monthShort interest in Northwest Biotherapeutics has recently decreased by 5.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by Institutions0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NWBO Stock News HeadlinesNorthwest Biotherapeutics Announces Expansion of Its Technical TeamOctober 26, 2026 | prnewswire.comNorthwest Biotherapeutics announces NHSBT collaboration to support DCVax-L production in the UKOctober 9, 2026 | msn.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionOctober 8, 2026 | prnewswire.comNorthwest Biotherapeutics highlights personalized cancer vaccine approach at NHS oncology conferenceOctober 6, 2026 | msn.comNorthwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual ...October 6, 2026 | finance.yahoo.comNorthwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology ConferenceOctober 6, 2026 | prnewswire.comNorthwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance CompanyAugust 6, 2026 | prnewswire.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.23 at the start of the year. Since then, NWBO stock has decreased by 26.8% and is now trading at $0.1684. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) issued its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company earned $810 thousand during the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Intel (INTC), NIO (NIO), Cel-Sci (CVM) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2026Today11/11/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year Founded1998Profitability EPS (Trailing Twelve Months)($18.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.16 million Net Margins-1,736.35% Pretax Margin-1,761.07% Return on EquityN/A Return on Assets-56.34% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual Sales$1.38 million Price / Sales222.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-4.21Miscellaneous Outstanding Shares1,823,970,000Free Float1,776,482,000Market Cap$307.16 million OptionableNot Optionable Beta-0.59 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:NWBO) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
